Home/Filings/4/0001209191-18-054084
4//SEC Filing

Latham John A 4

Accession 0001209191-18-054084

CIK 0001423824other

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 6:31 PM ET

Size

15.1 KB

Accession

0001209191-18-054084

Insider Transaction Report

Form 4
Period: 2018-10-01
Latham John A
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2018-10-01$6.76/sh+6,814$46,097268,692 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-10-0118,1850 total
    Exercise: $3.46Exp: 2022-06-12Common Stock (18,185 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-10-016,8146,821 total
    Exercise: $6.76Exp: 2024-02-10Common Stock (6,814 underlying)
  • Exercise/Conversion

    Common Stock

    2018-10-01$3.46/sh+18,185$63,011261,878 total
  • Sale

    Common Stock

    2018-10-01$15.25/sh18,445$281,314250,247 total
  • Sale

    Common Stock

    2018-10-01$15.97/sh6,554$104,692243,693 total
Footnotes (5)
  • [F1]The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.78 to $16.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
  • [F5]The shares subject to this stock option are fully vested.

Issuer

ALDER BIOPHARMACEUTICALS INC

CIK 0001423824

Entity typeother

Related Parties

1
  • filerCIK 0001604874

Filing Metadata

Form type
4
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 6:31 PM ET
Size
15.1 KB